Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study

BACKGROUND: Upadacitinib (UPA) is a selective JAK inhibitor recently approved for the treatment of psoriatic arthritis (PsA). In this post-approval study, we aimed to evaluate the effectiveness and safety of UPA over 24 weeks and identify clinical predictors of response, in a multicentric cohort of...

Descripción completa

Detalles Bibliográficos
Autores principales: Luchetti Gentiloni, Michele Maria, Paci, Valentino, Carletto, Antonio, Zabotti, Alen, Ramonda, Roberta, Chimenti, Maria Sole, Dagna, Lorenzo, Luciano, Nicoletta, Piccinelli, Anna, Giovannini, Ivan, Striani, Giovanni, Boffini, Nicola, Sandri, Gilda, Possemato, Niccolò, Pantano, Ilenia, Benfaremo, Devis, Salvarani, Carlo, Ciccia, Francesco, Selmi, Carlo, Moroncini, Gianluca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565976/
https://www.ncbi.nlm.nih.gov/pubmed/37821952
http://dx.doi.org/10.1186/s13075-023-03182-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565976/
https://www.ncbi.nlm.nih.gov/pubmed/37821952
http://dx.doi.org/10.1186/s13075-023-03182-9

Ejemplares similares